Cytokinetics, Incorporated (CYTK) has a negative trailing P/E of -10.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 100.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.90%, forward earnings yield 0.99%. PEG 0.20 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 29.5 | -0.21 | 5.14 | 4.56 | - |
| 2017 | -3.2 | 0.00 | 3.67 | 30.12 | - |
| 2018 | -3.2 | 0.13 | 13.26 | 10.92 | - |
| 2019 | -5.0 | -0.15 | -55.85 | 22.74 | - |
| 2020 | -10.5 | 0.44 | 11.83 | 24.02 | - |
| 2021 | -16.3 | -0.39 | 14.37 | 49.76 | - |
| 2022 | -10.6 | -0.19 | -38.14 | 43.51 | - |
| 2023 | -15.3 | -0.59 | -20.86 | 1,070.22 | - |
| 2024 | -8.9 | 2.56 | -38.91 | 285.13 | - |
| 2025 | -9.7 | -0.40 | -11.56 | 86.62 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.39 | $106.41M | $16.45M | 15.5% |
| 2017 | $-2.59 | $13.37M | $-127.79M | -955.9% |
| 2018 | $-1.95 | $31.5M | $-106.29M | -337.4% |
| 2019 | $-2.59 | $26.87M | $-149.05M | -554.8% |
| 2020 | $-2.54 | $55.83M | $-164.14M | -294% |
| 2021 | $-3.15 | $70.43M | $-242.37M | -344.1% |
| 2022 | $-4.48 | $94.59M | $-402.55M | -425.6% |
| 2023 | $-5.45 | $7.53M | $-526.24M | -6988.6% |
| 2024 | $-5.26 | $18.47M | $-589.53M | -3191.1% |
| 2025 | $-6.54 | $88.04M | $-784.96M | -891.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-6.41 | $-7.45 – $-4.55 | $91.21M | $57.81M – $176.14M | 14 |
| 2027 | $-4.78 | $-5.99 – $-3.22 | $372.26M | $330.63M – $482.7M | 13 |
| 2028 | $-2.12 | $-4.22 – $-0.81 | $843.51M | $826.19M – $860.83M | 14 |
| 2029 | $0.86 | $0.66 – $1.36 | $1.45B | $1.19B – $2.1B | 8 |
| 2030 | $4.25 | $3.27 – $6.75 | $2.21B | $1.82B – $3.21B | 12 |
